Elena Matsa has expertise and experience in a broad array of functions essential to successful allogeneic cell therapy manufacturing, including iPSC differentiation, genetic manipulation, phenotypic assay development, efficacy and safety assessment of therapeutic modalities, and in vitro disease modeling. For Cellistic and its affiliate company Ncardia, Elena manages key strategic technical projects, provides scientific leadership, and contributes to project proposals. After earning her PhD in stem cell biology in 2010, she worked as a post-doctoral research fellow at Stanford University, studying iPSC technology. She transitioned to the biopharmaceutical industry in 2017, working as a Scientist and, later, Director for drug discovery research. Elena’s work has been published in Cell Stem Cell, Nature Medicine, Science Translational Medicine and European Heart Journal, among others.Andy Holt brings more than 15 years of experience in cell and gene therapy to Cellistic. In his prior roles, he held business development, corporate development and management positions for CDMOs, driving commercial strategy and growth in adeno-associated virus (AAV) gene therapy manufacturing. In his role at Cellistic, Andy leverages his experience in scaling up cell and gene therapy platforms to help Cellistic clients reach their goals in allogeneic cell therapy.